Vallina, from the CRIS Immuno-Oncology Unit, in Madrid (Spain), explains that a new approach provides 'trained troops' of ...

This is best exemplified by chimeric antigen receptor (CAR) T-cells. Since first being tested in a patient nearly 15 years ago, six CAR T-cell products have been approved by the US Food and Drug ...

Jensen et al 17 showed that outcomes of 15 CD19- or CD20-specific chimeric antigen receptor T-cell (CAR-T) infusions in 4 patients were limited by short persistence of 1-7 days, attributed to ...

Tocilizumab -- an interleukin (IL)-6 receptor inhibitor -- was approved by the FDA in 2017 for the treatment of severe or ...

Cell and gene therapy: Dr. Jeff Hersh examines 25 years of technological advances In general, earlier stage cancers have ...

The therapy is currently in Phase I/Ib clinical development for patients with relapsed/refractory multiple myeloma.

Researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients. This discovery has fueled new strategies that ...

Legend Biotech's valuation is conservative, suggesting potential for significant appreciation and growth ahead. Click here to ...

You have full access to this article via your institution. To demonstrate the power of PCR–mediated recombination and provide an example of the general utility of the method, we constructed ...

Adicet Bio (ACET) reported ADI-001 clinical biomarker data from the Phase 1 GLEAN trial which further reinforces the potential of ...

Building on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases ...